Charles Gersbach

We're very excited to launch of the Duke Center for Advanced Genomic Technologies @DukeCAGT, a joint venture of @DukeEngineering @DukeMedSchool and @DukeTrinity. We are supporting collaborative research efforts to tackle grand challenges in genome sciences and engineering.

Led by Sean McCutcheon, Dahlia Rohm, and Nahid Iglesias - we are thankful to the editors and reviewers for their contributions to enhancing this review.

We propose remaining challenges and opportunities for epigenome editing, and provide a future outlook. We are incredibly enthusiastic about the pace of new technology development in this area, the fundamental discoveries it is enabling, and what it can do for patients!

We explain the technology and its context among other genome editing tools, provide a catalog of common epigenome editors, survey recent technical advances, and summarize use cases in functional genomics, cell engineering, and gene/cell therapy.

Epigenome editing is transforming biological sciences and medicine. We're grateful for the opportunity to publish this review of the field in @NatureBiotech. Check it out here: rdcu.be/dPjsJ

Epigenetic control is incredibly powerful for bolstering cell therapy. We’re very excited to continue to build on the foundation established with this publication.

Using a new CRISPR-based methodology, a team of researchers led by @cgersbach @DukeU has identified a “master regulator” gene capable of dramatically improving T-cell therapy performance >>> bit.ly/47vsnwN

Epigenetic CRISPR screening in human T cells reveals that BATF3 overexpression enhances T cell function, reduces exhaustion, and boosts CAR T cell potency in both in vitro and in vivo tumor models. #NBThighlight nature.com/articles/s4158…

We are incredibly thankful to our collaborators and co-authors, and our funding sources for supporting this new research direction! @somaticediting @ENCODE_NIH @IGVFConsortium @genome_gov @NSF @AllenInstitute @DukeU @DukeCAGT

This is our first report of a broader active area within our research group on T cell engineering. We are excited to repurpose the tools and protocols developed here for improve ACT and CAR-T for diverse applications. We’re looking forward to sharing more on these efforts soon!

Very happy to share our latest work today in @NatureGenet - "Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens" - led by @DukeUBME PhD student Sean McCutcheon. 1/n nature.com/articles/s4158… rdcu.be/dqHFO

Looking forward to a great meeting!